MAP2K7 and cancer: Moreover, accumulating evidence suggests that the combination of an MEK inhibitor, such as selumetinib, and a phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) inhibitor can be effective in many cancer therapies [25].